Best in class in vitro models to accurately predict in vivo outcomes.
Newcells Biotech is based at The Biosphere, a purpose-built complex for science-based businesses located on The Helix science campus in Newcastle upon Tyne, UK
The company was founded in 2015 as a spin-out biotechnology company from Newcastle University.
The company is founded on the technology and expertise of one of the UK’s leading centres for stem cell biology and is located alongside one of the largest research-intensive medical university and hospital complexes in the UK.
NEW THINKING
Human-induced pluripotent stem cell (hiPSC) lines are fast becoming instrumental in advances in disease modelling, drug development and drug toxicity. We can significantly improve the unpredictable and costly global drug discovery process by delivering the “best in biology” human tissue samples and converting these lines into specific cell types.
NEW APPROACHES
We create differentiated cells and incorporate them into novel pre-clinical assays covering both human and other key species using our iPSC and cell biology techniques.
NEW OPPORTUNITIES
We have the expertise to collaborate with multidisciplinary teams in industry and academia. We are experts in developing cells of the retina, kidney, liver, and lung – making simple models and complex miniature organs to mimic in-vivo human physiology.
NEW DISCOVERIES
Working with ethically sourced patient samples we can build in-vitro models of diseases to accelerate the exploration of targets and new chemical entities.
Newcells Biotech is based at The Biosphere, a purpose-built complex for science-based businesses located on The Helix science campus in Newcastle upon Tyne, UK
The company was founded in 2015 as a spin-out biotechnology company from Newcastle University.
The company is founded on the technology and expertise of one of the UK’s leading centres for stem cell biology and is located alongside one of the largest research-intensive medical university and hospital complexes in the UK.
NEW THINKING
Human-induced pluripotent stem cell (hiPSC) lines are fast becoming instrumental in advances in disease modelling, drug development and drug toxicity. We can significantly improve the unpredictable and costly global drug discovery process by delivering the “best in biology” human tissue samples and converting these lines into specific cell types.
NEW APPROACHES
We create differentiated cells and incorporate them into novel pre-clinical assays covering both human and other key species using our iPSC and cell biology techniques.
NEW OPPORTUNITIES
We have the expertise to collaborate with multidisciplinary teams in industry and academia. We are experts in developing cells of the retina, kidney, liver, and lung – making simple models and complex miniature organs to mimic in-vivo human physiology.
NEW DISCOVERIES
Working with ethically sourced patient samples we can build in-vitro models of diseases to accelerate the exploration of targets and new chemical entities.
Location: United Kingdom, England, Newcastle upon Tyne
Employees: 11-50
Phone: +44 191 580 6184
Total raised: $12.56M
Founded date: 2014
Investors 1
| Date | Name | Website |
| - | Northstar ... | northstarv... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 14.02.2024 | - | $2.95M | - |
| 01.03.2021 | - | $6.96M | - |
| 04.07.2018 | - | $2.65M | - |
Mentions in press and media 8
| Date | Title | Description |
| 09.09.2024 | Newcells Biotech launches Lung Ciliary Beat Frequency assay to enhance safety and efficacy profiling in preclinical drug development | Application of new CiliaBeat software to provide reliable and predictive data on the impact of drugs on cilia function Assay leverages Newcells’ complex lung small airway in vitro model to enable highly sensitive assessment of drug efficacy... |
| 06.08.2024 | The Future of Drug Development: How AI and Advanced Imaging are Shaping the Landscape | In the fast-paced world of drug development, innovation is the lifeblood that keeps the industry moving forward. Two recent advancements illustrate this point vividly: Molecular Devices' launch of the QPix Insights app and Newcells Biotech'... |
| 01.08.2024 | Newcells Biotech launches high-content and high-throughput imaging suite to advance pre-clinical drug development programmes | Investment in state-of-the-art imaging suite to accelerate data generation with physiologically-relevant in vitro models for deeper insights on drug effects in vivo Launch of advanced lung FMT assay provides extensive critical efficacy and ... |
| 14.02.2024 | Newcells Biotech Raises Further £2.35M in Funding | Newcells Biotech, a Newcastle, London, UK-based company which specializes in 3D models, raised $2.35M in funding. The round, which brought the total amount to £12M, saw participation from North East Venture Fund, European Regional Developme... |
| 01.03.2021 | Newcastle-based biotech Newcells Biotech grabs £5M for its 3D tissue models for drug discovery | In a latest development, Newcastle-based human stem cell model specialists, Newcells Biotech, have secured a total of £5.25 million worth of funding to accelerate their growth plans in the international life sciences market. Eyes to acceler... |
| 04.07.2018 | NVM leads investment in Newcells Biotech NVM Private Equity (NVM) has invested £1.5 million of growth capital into Newcastle based hiPSC company Newcells Biotech (Newcells) alongside existing investo... | Founded in 2015 and headquartered at the world-renowned International Centre for Life in Newcastle (an incubator space for young and established biotechnology companies) Newcells is a successful, early-stage, life-sciences spinout from Newc... |
| 04.07.2018 | hiPSC Maker Newcells Biotech Secures £2M in Funding | Newcells Biotech, a Newcastle upon Tyne, UK-based maker of human induced pluripotent stem cells (hiPSCs), secured £2m in funding. Backers included NVM Private Equity and Northstar Ventures. The company intends to use the funds to expand its... |
| - | Newcells Biotech | “Newcells Biotech are experts in building and applying functional in vitro models to improve clinical translation and drug discovery.” |